User login
Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.
Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).
Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.
Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.
Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source
Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.
Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).
Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.
Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.
Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source
Key clinical point: Increased cytokine S100A8/9 expression on the skin surface in infants with a high risk for atopic dermatitis (AD) at 2 months with filaggrin wild genotype (FLGwt), but not filaggrin loss-of-function mutations (FLGmut), is predictive of AD development and persistence in the first year of life.
Major finding: Increased S100A8/9 titers detected in skin swabs of the antecubital fossa at 8 weeks in infants with FLGwt, but not in those with FLGmut, were associated with AD development in the first year of life (P = .033) and AD persistence of between 6 and 12 months of age (P < .001).
Study details: This single-center study included 86 infants from the STOP AD trial who had at least one parent with a history of AD, asthma, or allergic rhinitis and had either FLGwt or FLGmut.
Disclosures: The cost of the sample analysis was funded by Janssen R&D and Johnson & Johnson Santé Beauté France and the product used in the study was provided by Johnson & Johnson Santé Beauté France. Six authors declared being employees of or having other ties with the Johnson & Johnson family of companies and others. Two authors are coauthors on a patent application in relation to the STOP-AD study. No declaration of conflicting interests was made by CNC.
Source: Stamatas GN, Sato T, Ni Chaoimh C, et al. Early skin inflammatory biomarker is predictive of development and persistence of atopic dermatitis in infants. J Allergy Clin Immunol. 2024 (Mar 7). doi: 10.1016/j.jaci.2024.02.018 Source